FDA Accepts MC2 Therapeutics’ NDA for Topical Plaque Psoriasis Treatment
The new treatment is the first cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis.
MC2 Therapeutics, a pharmaceutical company focused on novel PAD Technology-based topical therapies for chronic inflammatory conditions, announced on Nov. 20, 2019 that FDA accepted its new drug application (NDA) for Wynzora Cream (calcipotriene and betamethasone dipropionate) for the treatment of plaque psoriasis.
According to the company, the new treatment is the first cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. In a Phase III trial, the drug showed a higher efficacy compared to Taclonex Topical Suspension (calcipotriene and betamethasone dipropionate), a topical treatment for plaque psoriasis by Leo Pharma.
“We are very proud of the overall clinical profile of Wynzora Cream and look forward to continuing our interaction with [FDA] during the NDA review,” said Jesper J. Lange, president and CEO of MC2 Therapeutics, in a company press release. “In parallel we will continue our efforts to ensure widespread patient access to Wynzora Cream pending approval.”
Source: MC2 Therapeutics
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
